All News
Interesting, NWA by Dougados et al shows both Tofa and ADA may benefit pain in those who have controlled inflammatory component. ?real effect vs imperfect measures @RheumNow #EULAR2022 OP0052 https://t.co/aYBTaSDa3v https://t.co/dkLv1l5tFy
Links:
Richard Conway RichardPAConway ( View Tweet)
#POS0065 #EULAR2022 What is the nature of ILD progression in #Sjogren and is it mostly stable? A cohort study in Oslo (N=702) showed after 15 yrs follow-up, 45% had radiographic progression. Hence, need to monitor lung function test @RheumNow https://t.co/ga7qer27ks
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#POS0263 #EULAR2022 In #rituximab-treated RMD patients with undetectable humoral response to primary #COVID 💉, a study (N=84) found Re-Vaccination with mRNA (2 shots) was better than a Booster (1 shot). Lend support for current approach: 2 + 3rd Primary + Booster @RheumNow https://t.co/AH0wpVKbHc
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Burja et al. Dimethyl alpha-ketoglutarate has anti-inflammatory and anti-fibrotic effects on explanted systemic sclerosis skin. @RheumNow #EULAR2022 OP0095 https://t.co/PSbnVh6uta https://t.co/2ij9HgoU6Q
Links:
Richard Conway RichardPAConway ( View Tweet)
RheumNow Coverage of #EULAR2022 Presents Live Expert Discussions https://t.co/FeE0WfXw1z
Dr. John Cush RheumNow ( View Tweet)
Phase 3 RCT upadacitinib in nrAxSpA. Clinical (ASAS40), PRO, and radiologic response seen at week 14 vs placebo @RheumNow #EULAR2022 OP0016 https://t.co/s3Vf4QiiAD https://t.co/gzlxZ3sxHF
Links:
Richard Conway RichardPAConway ( View Tweet)
#EULAR2022 OP0073: Gender-specific assessment for MRI imaging criteria
⭐️Sex differences in axSpA - disease presentations, jt biomechanics, diagnostic delay in ♀️
⭐️Higher fat metaplasia in ♂️, Sclerosis in ♀️
⭐️Ankylosis much higher in ♂️ (DOR 40!)
@Rheumnow
Eric Dein ericdeinmd ( View Tweet)
#What’sHot? Axial PsA cohort as some drugs seem to work differently in axPsA vs axSpA Less HLAB27+, less male, 17% isolated axial in PsA #OP0026 @RheumNow #EULAR2022 @eular_org https://t.co/I0azSymVrr
Janet Pope Janetbirdope ( View Tweet)
Intra-articular morphine in knee arthritis. WHAT!? Not-surprisingly it doesn't work. Inferior to steroid and same as placebo. Still kudos to Haibel et al for answering this question @RheumNow #EULAR2022 OP0050 https://t.co/zjY36V9OCS https://t.co/j67omCQCxI
Links:
Richard Conway RichardPAConway ( View Tweet)
#POS0086PARE #EULAR2022 What #lupus symptoms/target mattered most to the patients?A survey in 342 found reduction in joint pain, rash & non-joint pain as most important. Reduced infection risk was the least. Important to be aware in assessing patients & guide studies @RheumNow https://t.co/pGXxklj1mt
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Minimal disease activity achivement by PsA domain over 2y, in guselkumab phase 3
Everyone goes on about skin efficacy with guselkumab, but pretty good early on for enthesitis & swollen joints too... has challenged my uninformed thinking!
POS1067 #EULAR2022 #IL23 @RheumNow https://t.co/chCWeFd05o
David Liew drdavidliew ( View Tweet)
↘️Education level🟰↗️risk of clinical RA in at risk patients. HR=1.8 although partially explained by ↗️ MRI inflammation at Dx.
Adjusted on smoking status, age and BMI.
Shall we follow this group of patients more closely?
OP0035 #EULAR2022 @RheumNow https://t.co/8EJZpaxn3k
Aurelie Najm AurelieRheumo ( View Tweet)
🔜 Remission in PsA : the earlier the better ⏰
Dutch cohort (DEPAR) 300+pts
Failure to achieve MDA 1yr post diagnosis
🧨worst QoL yr 1️⃣2️⃣&3️⃣
🧨↗️bioDMARDs use over time
🧨no recovery
#OP0028 #EULAR2022 @RheumNow https://t.co/IS6ySIQvBP
Aurelie Najm AurelieRheumo ( View Tweet)
PMR bursas are filled with macrophage subtypes esp CD68+, expressing IL-6 & GM-CSF.
PMR is now far from just a vibe - real science, real targets for therapy.
Not every day that PMR basic science makes it on stage, lovely from @VasculitisUMCG @jiemy_william
#EULAR2022 @RheumNow https://t.co/zem3JEosQL
David Liew drdavidliew ( View Tweet)
Jiemy et al. Phenotyping monocytes/macrophages in PMR. Synovial/bursal macrophages have pro-inflammatory phenotype with prominent IL-6 and GM-CSF response. Rationale for tocilizumab/mavrilimumab @RheumNow #EULAR2022 OP0015 https://t.co/53GJkL4BcP
Links:
Richard Conway RichardPAConway ( View Tweet)
Retrospective nation-wide italian study:
Long term exposure to :
🌫 PM10 ⬆️ risk of RA aOR 1.4 but not other AI diseases
🚗PM2.5 ⬆️ risk of RA aOR 1.6 CTDs aOR 1.1 IBDs aOR 1.2
OP0071 #EULAR2022 @Rheumnow https://t.co/HOOEnh7KWW
Aurelie Najm AurelieRheumo ( View Tweet)
Pre-clinical RA TREAT EARLIER Trial: #Plenary OP0070
RDBPCT eval temporary MTX vs PCB in 136 pts with arthralgias >2 weeks at risk for RA (MRI hand/forefoot w/subclinical inflammation) followed for 2 yrs; 1/3 +ACPA. Rx 1 yr can delay but won’t prevent RA. #EULAR2022 @rheumnow https://t.co/v1GWOBFstz
TheDaoIndex KDAO2011 ( View Tweet)
EULAR 2022 Featured Industry Abstracts
Review is a collection of several EULAR 2022 abstracts highlighted in recent press releases from companies sponsoring major clinical trials. You can search the EULAR site for these abstract and others here.
https://t.co/ggnAyuvAbl https://t.co/WjKDb70RkW
Links:
Dr. John Cush RheumNow ( View Tweet)
#OP0002 #EULAR2022 What immune tests to monitor during pregnancy in #lupus? A meta-analysis found:
💠32% had a flare (new IS or Pred>9mg/d)
💠⬇️C3 and/or C4 in 1st Trimester predicted LN or SLE flare
Worth checking C3/C4 in each trimester @RheumNow https://t.co/fPEXwReK7u https://t.co/BX6fzKzfvC
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#POS0183 #EULAR2022 Pooled analyses of 5 Belimumab RCTs showed better response vs PBO in those:
💠SLEDAI=>10
💠dsDNA+ve + ⬇️C3 and/ ⬇️C4
💠⬇️C3 and/ C4 pre-treatment
💠Response high regardless SDI, Steroid, #lupus duration
@RheumNow https://t.co/fLggazbRQu
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)